Extracellular Domain Protein (ECD)

DIMA Biotechnology offers over 1000 ECD proteins covering more than 600 single pass membrane protein targets. All the proteins were made using HEK293 mammalian cell secretion expression system to ensure the close-to-native structures and post-translational modifications of the target proteins. We also implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing tests, thermal stability tests, etc. 

Applications:

  • Immunogens for antibody drug development
  • Reagents used for CAR-T positive cell monitoring
  • Reagents for antibody screening and functional testing
  • Reagents for antibody affinity measurement
View All ECD Proteins

Immune checkpoints are a class of proteins that regulate tumor immune microenvironment.

They can be classified into two categories, costimulatory immune checkpoints, such as OX40, GITR, ICOS, etc.; and co-suppressive immune checkpoints, such as PD1, CTLA-4, etc.

Right now there are a number of FDA approved drugs on co-suppressive targets, such as Yervoy, anti-CTLA-4 monoclonal antibody, Keytruda, anti-PD-1 monoclonal antibody and Tecentriq, anti-PD-L1 monoclonal antibody.

pages-416107bc534d939 1

DIMA Biotechnology LTD provide a full spectrum of functional proteins of new CAR T-cell targets.

All the proteins were made by using HEK293 mammalian cell secretion expression system and we implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing Tests, thermal stability tests, etc.

pages-cvsdvdfffffb 1

In recent years, the biopharmaceutical market is growing rapidly.

Compared with small molecule drugs, antibody drugs exhibit higher specificity and selectivity.

Therefore, it showed tremendous progresses in the treatment of hematological cancers and autoimmune diseases.

Due to complex tumor immune microenvironment, the development of therapeutic antibody drugs for solid tumor is more challenging.

Latest News

 

CD73: A Potential Target in Cancer Immunotherapy

On September 25, 2024, I-Mab announced a strategic collaboration with Sanofi to develop, produce, and [...]

HER3/ERBB3: Dominating Cancer Therapy with ADCs and Beyond

On September 17, a collaboration between Daiichi Sankyo and Merck announced that patritumab deruxtecan, a [...]

Who Dominates the Billion-Dollar Market for Systemic Lupus Erythematosus Treatment?

According to a blog released by market intelligence provider Future Market Insights, Inc. (FMI) on [...]

Research Progress on BCMA-Targeted Therapies in Multiple Myeloma

On August 27, 2024, Legend Biotech’s BCMA CAR-T product, Carvykti® (generic name: ciltacabtagene autoleucel injection), [...]

TRPV1: An Important Target for Pain Treatment

Do you remember the temperature and touch receptor TRPV1 that made American scientists David Julius [...]

MC4R: A Niche Target in the Weight Loss Drug Market

On July 16, 2024, Dr. Roger Cone, co-founder of the preclinical biotech company Courage, published [...]

The glucagon receptor (GCGR):A Key Target in Glucose Metabolism

On June 25, 2024, at the 2024 American Diabetes Association (ADA) Scientific Sessions, Suzhou Innovent Biologics [...]

Research Progress on Targeting BCMA in Autoimmune Diseases

The B cell maturation antigen (BCMA), a target that gained prominence due to its association [...]